167 related articles for article (PubMed ID: 31905926)
1. Role of Metastasis-Related Genes in Cisplatin Chemoresistance in Gastric Cancer.
Nishiguchi Y; Oue N; Fujiwara-Tani R; Sasaki T; Ohmori H; Kishi S; Mori S; Mori T; Ikeda N; Matsumoto S; Wakatsuki K; Luo Y; Yasui W; Sho M; Kuniyasu H
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905926
[TBL] [Abstract][Full Text] [Related]
2. The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway.
Park J; Ko YS; Yoon J; Kim MA; Park JW; Kim WH; Choi Y; Kim JH; Cheon Y; Lee BL
Gastric Cancer; 2014; 17(3):423-30. PubMed ID: 24202965
[TBL] [Abstract][Full Text] [Related]
3. Poor expression of microRNA-135b results in the inhibition of cisplatin resistance and proliferation and induces the apoptosis of gastric cancer cells through MST1-mediated MAPK signaling pathway.
Zhou J; Chen Q
FASEB J; 2019 Mar; 33(3):3420-3436. PubMed ID: 30576232
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer.
Lin XM; Li S; Zhou C; Li RZ; Wang H; Luo W; Huang YS; Chen LK; Cai JL; Wang TX; Zhang QH; Cao H; Wu XP
Int J Biochem Cell Biol; 2019 Nov; 116():105610. PubMed ID: 31518663
[TBL] [Abstract][Full Text] [Related]
5. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of FAM3B Promotes Cisplatin Resistance in Gastric Cancer by Inducing Epithelial-Mesenchymal Transition.
Song C; Duan C
Med Sci Monit; 2020 May; 26():e921002. PubMed ID: 32442162
[TBL] [Abstract][Full Text] [Related]
7. Ginkgo biloba extract enhances chemotherapy sensitivity and reverses chemoresistance through suppression of the KSR1-mediated ERK1/2 pathway in gastric cancer cells.
Liu SQ; Xu CY; Qin MB; Tan L; Zhuge CF; Mao YB; Lai MY; Huang JA
Oncol Rep; 2015 Jun; 33(6):2871-82. PubMed ID: 25962735
[TBL] [Abstract][Full Text] [Related]
8. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs.
Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
Oncol Rep; 2005 Sep; 14(3):609-15. PubMed ID: 16077963
[TBL] [Abstract][Full Text] [Related]
9. METase/lncRNA HULC/FoxM1 reduced cisplatin resistance in gastric cancer by suppressing autophagy.
Xin L; Zhou Q; Yuan YW; Zhou LQ; Liu L; Li SH; Liu C
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2507-2517. PubMed ID: 31485766
[TBL] [Abstract][Full Text] [Related]
10. NIK‑ and IKKβ‑binding protein contributes to gastric cancer chemoresistance by promoting epithelial‑mesenchymal transition through the NF‑κB signaling pathway.
Fu ZH; Liu SQ; Qin MB; Huang JA; Xu CY; Wu WH; Zhu LY; Qin N; Lai MY
Oncol Rep; 2018 Jun; 39(6):2721-2730. PubMed ID: 29620292
[TBL] [Abstract][Full Text] [Related]
11. High mobility group box 1/toll-like receptor 4/myeloid differentiation factor 88 signaling promotes progression of gastric cancer.
Yue Y; Zhou T; Gao Y; Zhang Z; Li L; Liu L; Shi W; Su L; Cheng B
Tumour Biol; 2017 Mar; 39(3):1010428317694312. PubMed ID: 28347236
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
13. Boswellic acid sensitizes gastric cancer cells to Cisplatin-induced apoptosis via p53-mediated pathway.
Al-Bahlani S; Burney IA; Al-Dhahli B; Al-Kharusi S; Al-Kharousi F; Al-Kalbani A; Ahmed I
BMC Pharmacol Toxicol; 2020 Sep; 21(1):64. PubMed ID: 32867831
[TBL] [Abstract][Full Text] [Related]
14. Circular RNA circ_0026359 Enhances Cisplatin Resistance in Gastric Cancer via Targeting miR-1200/POLD4 Pathway.
Zhang Z; Yu X; Zhou B; Zhang J; Chang J
Biomed Res Int; 2020; 2020():5103272. PubMed ID: 32855967
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo.
Zhang J; Zhu JS; Zhou Z; Chen WX; Chen NW
Oncol Rep; 2012 May; 27(5):1511-9. PubMed ID: 22246223
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance.
Wu QN; Liao YF; Lu YX; Wang Y; Lu JH; Zeng ZL; Huang QT; Sheng H; Yun JP; Xie D; Ju HQ; Xu RH
Cancer Lett; 2018 Jan; 412():243-255. PubMed ID: 29050982
[TBL] [Abstract][Full Text] [Related]
17. miR-492 promotes chemoresistance to CDDP and metastasis by targeting inhibiting DNMT3B and induces stemness in gastric cancer.
Wu S; Xie J; Shi H; Wang ZW
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32065219
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo.
Zhang LL; Zhang J; Shen L; Xu XM; Yu HG
Mol Med Rep; 2013 May; 7(5):1387-90. PubMed ID: 23546174
[TBL] [Abstract][Full Text] [Related]
19. Functional and transcriptomic characterization of cisplatin-resistant AGS and MKN-28 gastric cancer cell lines.
Mora-Lagos B; Cartas-Espinel I; Riquelme I; Parker AC; Piccolo SR; Viscarra T; Reyes ME; Zanella L; Buchegger K; Ili C; Brebi P
PLoS One; 2020; 15(1):e0228331. PubMed ID: 31990955
[TBL] [Abstract][Full Text] [Related]
20. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
Kim R; Tanabe K; Inoue H; Toge T
Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
